News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
723,005 Results
Type
Article (43836)
Company Profile (318)
Press Release (678851)
Section
Business (211978)
Career Advice (2100)
Deals (36414)
Drug Delivery (98)
Drug Development (82323)
Employer Resources (173)
FDA (16707)
Job Trends (15329)
News (356287)
Policy (33394)
Tag
Academia (2695)
Alliances (52404)
Alzheimer's disease (1346)
Approvals (16688)
Artificial intelligence (235)
Bankruptcy (365)
Best Places to Work (11960)
Biotechnology (224)
Breast cancer (236)
Cancer (1811)
Cardiovascular disease (133)
Career advice (1753)
CAR-T (139)
Cell therapy (389)
Clinical research (66246)
Collaboration (726)
Compensation (388)
COVID-19 (2655)
C-suite (181)
Data (1729)
Diabetes (224)
Diagnostics (6572)
Earnings (87357)
Employer resources (150)
Events (116006)
Executive appointments (611)
FDA (17687)
Funding (652)
Gene therapy (270)
GLP-1 (678)
Government (4470)
Healthcare (19528)
Infectious disease (2776)
Interviews (324)
IPO (16815)
Job creations (3827)
Job search strategy (1496)
Layoffs (456)
Legal (8120)
Lung cancer (262)
Manufacturing (250)
Medical device (14017)
Medtech (14022)
Mergers & acquisitions (20005)
Metabolic disorders (586)
Neuroscience (1776)
NextGen: Class of 2025 (6851)
Non-profit (4619)
Northern California (2230)
Obesity (319)
Opinion (210)
Patents (184)
People (59231)
Phase I (20781)
Phase II (29166)
Phase III (21620)
Pipeline (804)
Postmarket research (2584)
Preclinical (8857)
Radiopharmaceuticals (260)
Rare diseases (341)
Real estate (6239)
Regulatory (22594)
Research institute (2455)
Resumes & cover letters (362)
Southern California (1917)
Startups (3847)
United States (19819)
Vaccines (652)
Weight loss (220)
Date
Today (222)
Last 7 days (863)
Last 30 days (2952)
Last 365 days (35345)
2025 (5684)
2024 (36281)
2023 (41175)
2022 (52428)
2021 (57023)
2020 (55645)
2019 (48443)
2018 (36474)
2017 (33577)
2016 (33187)
2015 (39391)
2014 (32999)
2013 (28038)
2012 (30279)
2011 (30882)
2010 (28846)
Location
Africa (758)
Arizona (220)
Asia (40283)
Australia (6712)
California (5109)
Canada (1771)
China (425)
Colorado (235)
Connecticut (247)
Europe (88109)
Florida (746)
Georgia (181)
Illinois (492)
Indiana (279)
Japan (128)
Maryland (777)
Massachusetts (3926)
Michigan (220)
Minnesota (355)
New Jersey (1444)
New York (1451)
North Carolina (912)
Northern California (2230)
Ohio (180)
Pennsylvania (1157)
South America (1152)
Southern California (1917)
Texas (743)
Utah (160)
Washington State (495)
723,005 Results for "microdose therapeutx formerly microdose technologies inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Apex Labs files IND with FDA for microdose psilocybin study
Apex Labs Ltd. (APEX or the Company) is pleased to announce the filing of an IND application with the U.S. Food and Drug Administration (FDA) for APEX-002-B01-02, a pioneering pharmacokinetics and driving simulator study of APEX-52 take home microdose psilocybin.
June 20, 2024
·
4 min read
Press Releases
MindBio Announces Sustained Antidepressant Response 3-Months Post Treatment in Microdosing Depression Clinical Trials
August 19, 2024
·
5 min read
BioMidwest
Eyenovia Showcases Microdose Array Print (MAP™) Technology at CES 2023 in Las Vegas
Eyenovia, Inc., a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in connection with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, showcased the Microdose Array Print Technology at CES 2023 in Las Vegas, Nevada, from Jan. 5-8.
January 31, 2023
·
4 min read
Wellbeing Digital to Participate in the Microdose Psychedelic Capital Conference
Wellbeing Digital Sciences Inc. will participate in Microdose’s Psychedelic Capital: September 2022 Conference to be held virtually on September 29, 2022 at 1:30 p.m. ET.
September 23, 2022
·
3 min read
MindBio Therapeutics CEO Demonstrates how 1 Million Microdoses of LSD can Potentially be Used to Treat Depression at Scale
MindBio Therapeutics Corp. demonstrates how 1 million microdoses of LSD could potentially benefit tens of thousands of patients with Depression.
May 30, 2023
·
5 min read
Drug Development
MindBio Therapeutics World First Phase 2 Take-Home LSD-Microdosing Clinical Trial in Patients with Major Depressive Disorder Begins Pre-Screening Participants
MindBio Therapeutics Corp. is pleased to have started pre-screening for participant entry into Phase 2 LSD-Microdosing clinical trials.
July 19, 2023
·
5 min read
MindBio Therapeutics Begins Recruitment of Participants for World First LSD-Microdosing Clinical Trial in Cancer Patients Experiencing Emotional Distress
MindBio Therapeutics Corp. is pleased to have started selection of participants for its Phase 2 randomized double-blind and placebo controlled clinical trial in advanced stage cancer patients using microdoses of Lysergic Acid Diethylamide (LSD) and Meaning Centred Psychotherapy in a world’s first LSD take-home 6-week trial involving a total of 40 participants.
July 25, 2023
·
5 min read
Drug Development
MindBio Therapeutics Ethics Approval for Landmark World First Phase 2 Clinical Trial of Take-Home LSD-Microdosing for Major Depressive Disorder
MindBio Therapeutics Corp. is pleased to announce that ethics approval has been received for a world’s first Phase 2a take home LSD-Microdosing clinical trial in patients with Major Depressive Disorder.
May 23, 2023
·
6 min read
Apex Labs Meets Endpoints in First-of-its-Kind Take Home Microdose Psilocybin Clinical Trial
Apex Labs Ltd. (APEX or the Company) is pleased to announce the completion of the first-ever take home microdose psilocybin clinical trial, meeting all endpoints over a two month period with no adverse events.
March 29, 2023
·
5 min read
Drug Development
MindBio Therapeutics Nears Completion of Landmark Phase 2a LSD Microdosing (MB22001) Clinical Trial in Depressed Patients
MindBio Therapeutics Corp. announces it is nearing the completion of its Phase 2a clinical trial using MB22001 in patients with Major Depressive Disorder.
January 30, 2024
·
5 min read
1 of 72,301
Next
